1 - 12 of 12
Dr. Seif's research centers on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The long-term goal of her research is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.
The principal goal of Dr. Simmons' research program is to elucidate the underlying molecular mechanisms that link an aberrant intrauterine milieu to the later development of diseases in adulthood. She has made many seminal contributions to the understanding of the role that epigenetic modifications play in developmental programming of obesity and type 2 diabetes.
Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.